- Company
- Eliquis generics will soon return to market
- by Kim, Jin-Gu Jul 3, 2024 05:50am
- The patent for Eliquis (apixaban), a direct-acting oral anticoagulant (DOAC) worth KRW 80 billion a year, will expire in September. As such, generic versions of Eliquis, which were withdrawn from the market in 2021 due to the Supreme Court's reversed decision, will re-enter the market thereafter. The return of generics is expected to once
- Company
- New drug 'Aquipta' for migraine available for prescriptions
- by Eo, Yun-Ho Jul 3, 2024 05:50am
- The new drug 'Aquipta,' an oral migraine treatment, is becoming available in general hospitals in South Korea. According to industry sources, AbbVie Korea’s Aquipta (atogepant), an oral calcitonin gene-related peptide (GRRP) receptor antagonist for migraine treatment, has passed the drug committee (DC) of the ‘Big 5’ tertiary general
- Company
- CSL Behring’s hemophilia B Tx Idelvion is reimbursed in KOR
- by Kang, Hye-Kyung Jul 3, 2024 05:50am
- CSL Behring Korea's hemophilia B treatment Idelvion (albutrepenonacog alfa,) will be reimbursed by Korea’s national health insurance starting in July for the treatment of adult and pediatric patients. Idelvion is approved for the control and routine prophylaxis of bleeding in adults and pediatric patients and for perioperative management
- Company
- Daewoong and LG Chem launch Humira biosimilar 'Xelenka'
- by Kim, Jin-Gu Jul 3, 2024 05:50am
- Daewoong Pharmaceutical and LG Chem said on July 1st that they have launched 'Xelenka,' a Humira (adalimumab) biosimilar. Daewoong Pharmaceutical and LG Chem signed a distributer agreement for domestic sales earlier. Under the agreement, LG Chem will supply Xelenka to Daewoong Pharmaceutical, and Daewoong will handle domestic sales and
- Company
- Hugel signs distribution partnership agreement with Benev
- by Nho, Byung Chul Jul 2, 2024 05:49am
- The global total medical aesthetics company Hugel(Chair: Suk-yong Cha) will officially enter the U.S. market through a strategic partnership with the U.S.-based Benev Company. The company began discussions on a partnership to sell its botulinum toxin product ‘(Letybo, Korean brand name: Botulax)’ in the U.S. in August last year, and f
- Company
- PNH drug Voydeya is approved…new treatment option for PNH
- by Hwang, Byung-woo Jul 2, 2024 05:49am
- A new option for adult patients with paroxysmal nocturnal hemoglobinuria (PNH) has been introduced in Korea with the approval of Voydeya (danicopan), a first-in-class oral factor D inhibitor. Voydeya is AstraZeneca Korea's PNH treatment that was approved by the Ministry of Food and Drug Safety (MFDS) on March 28th. Voydeya is a first-in
- Opinion
- [Reporter’s View] 'all-comers' with strict criteria
- by Eo, Yun-Ho Jul 2, 2024 05:48am
- Drugs that are intended for use regardless of any conditions are strictly regulated. In the pharmaceutical industry, 'all-comers' refers to a drug indication that can be prescribed at any treatment stage, regardless of conditions. Drugs with all-comers indications have demonstrated their efficacy regardless of receptors or genetic mu
- Policy
- GSK will discontinue supply of Infanrix IPV
- by Lee, Tak-Sun Jul 2, 2024 05:48am
- GlaxoSmithKline has decided to discontinue supply of its ‘Infanrix IPV’ vaccine, which protects against diphtheria, tetanus, pertussis, and polio in children, in South Korea. Infanrix IPV and Sanofi Pasteur's ‘Tetraxim’ are the only DTaP-IPV vaccines used in the National Immunization Program (NIP), raising concerns about the shortage o
- Company
- GLP-1 uses↑…targets MASH, diabetes, and obesity
- by Son, Hyung-Min Jul 1, 2024 05:48am
- New drug candidates of the GLP-1 class target metabolic dysfunction-associated steatohepatitis (MASH) in addition to diabetes and obesity. Global pharmaceutical companies, such as Novo Nordisk, Eli Lily, Boehringer Ingelheim, and Korean pharmaceutical companies, including Dong-A ST and D&D pharmatech, are developing GLP-1 agents for the treat
- Company
- Companies to focus on developing trispecific antibodies
- by Son, Hyung-Min Jul 1, 2024 05:48am
- The pharmaceutical industry in South Korea and overseas has begun developing trispecific antibodies that bind three targets. Previously, these companies focused on bispecific antibodies, which can bind simultaneously to two different antigens or two antigenic epitopes on a single antigen. Crossing the blood-brain barrier (BBB) can increase th
